TG103

Last updated October 06, 2025

TG103 is an experimental GLP-1 receptor agonist and Fc fusion protein combination, developed by CSPC Pharmaceutical Group.^[1]

References

↑ Jin, Jiangli; Cui, Gang; Mi, Na; Wu, Wei; Zhang, Xin; Xiao, Chunyan; Wang, Jing; Qiu, Xueying; Han, Mai; Li, Ziyan; Wang, Lei; Lu, Tong; Niu, Huikun; Wu, Zhaoxi; Li, Jintong (1 June 2023). "Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects". European Journal of Pharmaceutical Sciences. 185 106448. doi: 10.1016/j.ejps.2023.106448 . PMID 37062422. S2CID 258166248.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Jin, Jiangli; Cui, Gang; Mi, Na; Wu, Wei; Zhang, Xin; Xiao, Chunyan; Wang, Jing; Qiu, Xueying; Han, Mai; Li, Ziyan; Wang, Lei; Lu, Tong; Niu, Huikun; Wu, Zhaoxi; Li, Jintong (1 June 2023). "Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects". European Journal of Pharmaceutical Sciences. 185 106448. doi: 10.1016/j.ejps.2023.106448 . PMID 37062422. S2CID 258166248.

[1]